Latest Capital Raises News

SportsHero Limited has arranged a $1 million unsecured loan facility to support its working capital needs, with flexible monthly drawdowns and a fixed 10% interest rate. The company has already drawn $100,000 from this facility, signaling ongoing liquidity management efforts.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Connected Minerals Ltd has successfully raised $5.1 million to fuel its aggressive uranium exploration in Namibia, reporting impressive high-grade rock chip results that set the stage for maiden drilling in early 2025.

Peregrine Gold secures a significant $1 million commitment from its largest shareholder, Yandal Investments, strengthening its entitlement offer ahead of the project sale to Capricorn Metals.

Peregrine Gold Limited has updated its prospectus to reveal a significant increase in share commitments from its largest shareholder, Yandal Investments, alongside key directors’ participation in the capital raise.

Godolphin Resources reports significant drilling success at Lewis Ponds with thick massive sulphide intersections and advances its Narraburra Rare Earths project with high-value carbonate samples, supported by a strong capital raise.

Neometals Ltd has bolstered its financial position with a A$7.1 million capital raise while progressing key projects including the commissioning of a lithium-ion battery recycling plant in Germany and preparing for maiden gold drilling at Barrambie.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.

Vonex Limited reports solid operational improvements and customer satisfaction in Q2 FY25, while endorsing Maxo Telecommunications’ takeover offer and planning a $13 million capital raise to manage debt.

Vonex Limited reported a net cash inflow of $779,000 from operating activities in Q4 2024, maintaining a solid cash position despite accelerated debt repayments following a change of control.